DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated
A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.
Company
Pharmaceutical intelligence for DB Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.